"The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart "...
(Generic versions may still be available.)
Because thrombolytic therapy increases the risk of bleeding, Streptase, Streptokinase, is contraindicated in the following situations:
- active internal bleeding
- recent (within 2 months) cerebrovascular accident, intracranial or intraspinal surgery (see WARNINGS)
- intracranial neoplasm
- severe uncontrolled hypertension
Streptokinase should not be administered to patients having experienced severe allergic reaction to the product.
Last reviewed on RxList: 10/7/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Streptase Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.